London
· Delayed Price · Currency is GBP · Price in USD Dynavax Technologies Company Description
Dynavax Technologies Corporation, a commercial stage biopharmaceutical company, focuses on developing and commercializing vaccines in the United States.
It markets HEPLISAV-B, a hepatitis B vaccine for prevention of infection caused by all known subtypes of hepatitis B virus in age 18 years and older in the United States and Europe.
The company also manufactures and sells CpG 1018, the adjuvant used in HEPLISAV-B. Dynavax Technologies Corporation has a collaboration agreement with Valneva Scotland Limited; Zhejiang Clover Biopharmaceuticals, Inc.; Clover Biopharmaceuticals (Hong Kong) Co., Limited; Biological E.
Limited; PT Bio Farma; Medigen Vaccine Biologics; and Serum Institute of India Pvt. Ltd. The company was formerly known as Double Helix Corporation and changed its name to Dynavax Technologies Corporation in September 1996.
The company was incorporated in 1996 and is headquartered in Emeryville, California.
| Country | United States |
| Founded | 1996 |
| Industry | Medical - Pharmaceuticals |
| Sector | Healthcare |
| Employees | 408 |
| CEO | Ryan Spencer |
Contact Details
Address: 2100 Powell Street EmeryVille, Delaware 94608 United States | |
| Phone | 510 848 5100 |
| Website | dynavax.com |
Stock Details
| Ticker Symbol | 0IDA |
| Exchange | London Stock Exchange |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| ISIN Number | US2681582019 |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Ryan Spencer | Chief Executive Officer and Director |
| David F. Novack | President and Chief Operating Officer |
| Kelly MacDonald CPA | Senior Vice President and Chief Financial Officer |
| Dr. Robert Janssen M.D. | Chief Medical Officer and Senior Vice President of Clinical Development, Medical and Regulatory Affairs |
| Justin Burgess | Chief Accounting Officer and Controller |
| Jeff P. Coon | Senior Vice President and Chief Human Resources Officer |
| Paul Cox | Vice President of Investor Relations and Corporate Communications |
| John L. Slebir | Senior Vice President and General Counsel |
| Donn Casale | Senior Vice President and Chief Commercial Officer |
| Dr. Dong Yu | Senior Vice President of Research |